Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Recommendation of “Buy” by Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $59.60.

A number of research firms have issued reports on JANX. Cantor Fitzgerald began coverage on Janux Therapeutics in a report on Wednesday, March 20th. They set an “overweight” rating and a $100.00 target price for the company. Bank of America raised their price objective on Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, March 13th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. Wedbush restated an “outperform” rating and issued a $53.00 price objective on shares of Janux Therapeutics in a report on Monday, March 11th. Finally, BTIG Research initiated coverage on Janux Therapeutics in a report on Thursday, March 21st. They issued a “buy” rating and a $62.00 price objective for the company.

Janux Therapeutics Trading Down 2.4 %

JANX stock opened at $37.92 on Thursday. The stock has a 50-day moving average price of $23.71 and a two-hundred day moving average price of $14.23. The stock has a market cap of $1.96 billion, a PE ratio of -28.30 and a beta of 4.31. Janux Therapeutics has a 1 year low of $5.65 and a 1 year high of $58.69.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its stake in Janux Therapeutics by 2.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 47,690 shares of the company’s stock valued at $628,000 after purchasing an additional 1,127 shares during the last quarter. Rhumbline Advisers lifted its stake in Janux Therapeutics by 4.5% in the 1st quarter. Rhumbline Advisers now owns 26,849 shares of the company’s stock valued at $325,000 after purchasing an additional 1,158 shares during the last quarter. State of Wisconsin Investment Board lifted its stake in Janux Therapeutics by 14.3% in the 2nd quarter. State of Wisconsin Investment Board now owns 13,202 shares of the company’s stock valued at $157,000 after purchasing an additional 1,647 shares during the last quarter. American International Group Inc. lifted its position in Janux Therapeutics by 25.3% during the first quarter. American International Group Inc. now owns 8,813 shares of the company’s stock worth $126,000 after acquiring an additional 1,782 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Janux Therapeutics by 149.4% during the first quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company’s stock worth $40,000 after acquiring an additional 2,003 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.